Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Our unwavering commitment to improving patient care is demonstrated every day through unique patient and physician programs and our ongoing collaboration with patients, physicians and advocacy groups. Building collaborative relationships that foster innovation is the key to our success.
Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) and Azur Pharma Limited announced that the companies have agreed to combine in an all-stock transaction that creates a specialty pharmaceutical company incorporated in Ireland with a diversified portfolio of products currently marketed in the United States (US). The combined company would be named Jazz Pharmaceuticals plc.
Azur Pharma is a privately-held, profitable specialty pharmaceutical company headquartered in Dublin, Ireland with US operations in Philadelphia. The company markets ten specialty pharmaceutical products in the US in the central nervous system (CNS) and women’s health areas, with expected 2011 net sales of approximately $95 to $100 million.
The combined company is expected to have a diversified revenue base from 12 products currently marketed in the US in the CNS and women’s health areas. These include Jazz Pharmaceuticals’ currently marketed products, Xyrem® (indicated to treat the two key symptoms of narcolepsy) and Luvox CR® (indicated to treat obsessive compulsive disorder), and the Azur Pharma marketed product portfolio which includes Prialt® (indicated for refractory severe chronic pain), FazaClo® (indicated for treatment resistant schizophrenia), two additional CNS products and a portfolio of women’s health products led by Elestrin® (for vasomotor symptoms associated with menopause). The combined company would also have a pipeline of lower-risk development programs including line extensions for the clozapine franchise and certain branded women’s health products. Full prescribing information about each product is available on its website.
For further information see www.jazzpharmaceuticals.com.
Simulations Plus Inc. (Nasdaq:SLP) announced that it has submitted a bid to purchase substantially all of the assets of Entelos, Inc., in an auction supervised by and in accordance with certain bidding procedures approved by the United States Bankruptcy Court for the District of Delaware and pursuant to the provisions of Section 363 of the U.S. Bankruptcy Code. The auction will take place on September 21, 2011, and, if the Company’s bid is selected as the highest or best bid, then a sale hearing is expected to be held on September 23, 2011, to approve the sale of the assets.
Simulations Plus, Inc. develops and produces software for use in pharmaceutical research and education, as well as provides contract research services to the pharmaceutical industry.
Enzo Biochem Inc. (ENZ)
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since ENZ was founded in 1976, their strategic focus has been on the development of enabling technologies in the life sciences field.
Biotechnology is essentially the use of technology to make biological processes benefit mankind. There are some advantages included below:
” The design of diagnostic kits
” The creation of genome analysis tools through bioinformatics
” Genetic engineering techniques to improve food crops
” Molecular biology method to help understand the nature of diseases
” Finding targets for drugs
” Molecular breeding methods to help improve livestock
” Creation of genetically modified foods to feed the ever growing world population
” Use of DNA fingerprinting in the court of law
” Use of the PCR reaction to clone DNA and make millions of identical copies
” Use of stem cells to treat diseases
” Diagnosing genetic disorders
Enzo Biochem Inc. recently announced that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.
The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.
Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.
For more information about Enzo Biochem Inc. visit its website: http://www.enzo.com
Cleantech Transit, Inc. (CLNO)
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.
Biomass is a broad term used to describe any organic material or resource which is derived from plant or animal matter. This includes wood, food crops, grass and woody plants, agriculture and forestry residues, and organic components of municipal and industrial wastes. Biomass excludes organic material which has been transformed via geological processes to fossil fuels such as coal, oil or natural gas.
Biomass can reduce dependence on foreign oil through production of biofuels and provide a boost for agricultural and forest industries by turning low value wastes into high value fuels, chemicals and electricity. The chemical composition of biomass varies substantially, because of the broad range of materials involved, but the main components are moisture, carbohydrates or sugars, lignin, and ash.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com
TheStreet, Inc. (Nasdaq:TST) announced the official re-launch of its two most popular premium services, RealMoney and RealMoney Pro (formerly known as RealMoney Silver). The services have been dramatically upgraded with a modern redesign and superior user interface along with even more actionable analysis, expert intelligence and state-of-the-art tools that subscribers can use to improve their investment strategies.
TheStreet, Inc., together with its subsidiaries, operates as a digital financial media company in the United States.
No comments:
Post a Comment